CO-TECHSTARS
6.1.2022 14:02:13 CET | Business Wire | Press release
Techstars, a global investment business that provides access to capital, one-on-one mentorship, and customized programming for early-stage entrepreneurs, has created two new leadership roles as the company continues to scale to serve more founders around the world. With $850 million in assets under management, 47 accelerator programs in 17 countries, and a global alumni base of more than 2,700 companies, both roles will provide strategic and operational support to thousands of entrepreneurs. Athreya and Moussavou will report directly to the company’s CEO, Maelle Gavet.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220106005289/en/
“Techstars has an unprecedented ability to impact entrepreneurs through our unique pre-seed investment model that identifies exceptional entrepreneurs worldwide and supports them operationally and financially as they build their businesses,” stated Gavet. “We count on globally experienced executives with the ability to think big-picture, enabling the organization to operate at scale which is why both Marie and Rupa are such wonderful additions to our global management team.”
As the company’s first Chief Accelerator Investments Officer, Rupa Athreya will lead a worldwide team of more than 75 investment professionals who represent Techstars in 37 cities around the world. Techstars operates under the principle that the best founders can come from anywhere, running programs locally in the cities where the entrepreneurs operate or seek to grow. Techstars maintains a small class size ranging from 10 to 12 portfolio companies and runs multiple programs in cities with larger entrepreneur ecosystems. Techstars’ Accelerator Investment Team invested approximately $94 million last year and will continue to grow its portfolio as investors around the world seek to invest in viable early-stage companies. Overseeing this decentralized approach requires a seasoned executive with a strategic mindset, strong operational skills and global experience.
Having worked at global firms such as OppenheimerFunds, JPMorgan Chase, Bloomberg and McKinsey, Athreya has most recently been an independent consultant advising startups and new businesses as well as global financial institutions on strategy, innovation, and go-to-market execution. She has close to 20 years of expertise in building and launching new businesses and products, having led product development at OppenheimerFunds, founded a robo-advisor at Bloomberg and launched the Chase Private Client business at JPMorgan Chase. She has a Ph.D. in Economics from Yale University, a B.A. in Philosophy, Politics and Economics from Oxford University and a B.A. in Economics from the University of Delhi. She will continue to be based out of New York, NY.
As Techstars’ first Chief Portfolio Services Officer, Marie Moussavou will be responsible for advancing growth, providing infrastructure support and investment opportunities for Techstars’ more than 6,500 alumni founders as they lead their companies through later stages. Portfolio Services provides capital and funding, business development and talent connections, mentorship, and knowledge exchange for Techstars’ network of founders, investors, mentors and innovation partners. With this ever-growing network, the Portfolio Services team under Moussavou’s leadership will maintain deep, personal relationships with founders while leveraging robust data management skills to offer founders customized and scalable support.
Moussavou has a proven track record of scaling high growth, customer-focused organizations through innovation and operational excellence. Most recently she worked at Amazon for 15 years in various senior roles, including Technical Advisor to the SVP for International, Director of Alexa Europe, and Director of Operations for Amazon Transportation Services Europe. Marie has an MBA from the London Business School and lives in London, U.K., where she will continue to be based.
About Techstars
The Techstars worldwide network helps entrepreneurs succeed. Founded in 2006, Techstars began with three simple ideas—entrepreneurs create a better future for everyone, collaboration drives innovation, and great ideas can come from anywhere. Now we are on a mission to enable every person on the planet to contribute to, and benefit from, the success of entrepreneurs. In addition to operating accelerator programs and venture capital funds, we do this by connecting startups, investors, corporations, and cities to help build thriving startup communities. Techstars has invested in more than 2,800 companies with a combined market cap of more than $195B. www.techstars.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220106005289/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
